A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study.
Wen-Chuan WuJiann-Torng ChenChing-Yao TsaiChien-Liang WuCheng-Kuo ChengYun-Dun ShenArslan TsaiPei-Chang WuPublished in: BMC ophthalmology (2020)
Treatment with ranibizumab 0.5 mg resulted in significant improvements in visual outcomes among treatment-naïve Taiwanese patients with nAMD. Early treatment and frequent dosing in the real-world setting may be the key to achieving better outcomes.